Dermatol. praxi. 2015;9(2):73-76

Naftitine in the management of dermatomycoses

doc.MUDr.Ivana Kuklová, CSc.
Dermatovenerologická klinika 1. LF UK a VFN

Naftifine is a member of allylamine antimycotics that possesses only topical activity, has fungicidal mode of action, and is effective and

safe in the management of superficial dermatomycoses. In vitro and in vivo bioavailability studies have demonstrated that naftifine

penetrates the stratum corneum in sufficient concentration to inhibit the growth of dermatophytes. Rapid onset of clinical activity and

favorable data on sustained clearance of infection have been documented with naftifine.

Keywords: naftifine, allylamine, dermatophytes, tinea

Published: June 22, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kuklová I. Naftitine in the management of dermatomycoses. Dermatol. praxi. 2015;9(2):73-76.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Skořepová M, Hubka V, Polášková S, Stará J, Čmoková A. Naše první zkušenosti s infekcemi vyvolanými Arthroderma benhamiae (Trichophyton sp.). Čes-slov Derm, 2014; 89(4): p. 192-198.
    2. Borelli C, Schaller M, Niewerth M, et al. Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi. Chemotherapy. 2008; 54: 245-259. Go to original source...
    3. Del Rosso JQ, Kircik LH. Optimizing topical antifungal therapy for superficial cutaneous fungal infections: focus on topical naftifine for cutaneous dermatophytosis. J Drugs Dermatol 2013; 12(11 Suppl): 165-71.
    4. Czok R. Preclinical evaluation of Exoderil (naftifine). Part II. Mechanism of action, absorption, metabolism and excretion. Mykosen. 1987; 30(Suppl 1): 28-31. Go to PubMed...
    5. Slíva J. Účinek naftifinu na mykózy a srovnání s dalšími antimykotiky. Dermatologie pro praxi, 2013; 7(2).
    6. El-Gohary M, van Zuuren EJ, Fedorowicz Z, Burgess H, Doney L, Stuart B, Moore M, Little P. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst Rev. 2014; 8: Epub 2014 Aug 4. Go to original source... Go to PubMed...
    7. Gip L, Brundin G. A double-blind, two group multicentre study, comparing naftifine 1 % cream with placebo cream in the treatment of tinea cruris. Mykosen. 1987; 30: (Suppl 1)38-41. Go to PubMed...
    8. Millikan LE, Galen WK, Gewirtzman GB, et al. Naftifine cream 1 % versus econazole cream 1 % in the treatment of tinea cruris and tinea corporis. J Am Acad Dermatol. 1988; 18: 52-56. Go to original source... Go to PubMed...
    9. Kuklová, I. Epidemiologie dermatofytóz v materiálu Dermatovenerologické kliniky. Medical tribune, 2012; 16(8): 4-5.
    10. Schaude M, Ackerbauer H, Mieth H. Inhibitory effect of antifungal agents on germ tube formation in Candida albicans. Mykosen. 1987; 30: 281-287. Go to original source... Go to PubMed...
    11. Zaias N, Astorga E, Cordero CN et al. Naftifine cream in the treatment of cutaneous candidiasis. Cutis. 1988; 42: 238-240. Go to PubMed...
    12. Nolting S. Investigation of the antibacterial effect of the antifungal agent naftifine: left versus right clinical comparative study between naftifine and gentamycin in pyoderma. Mykosen. 1987; 30(Suppl 1): 124-128.

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.